Literature DB >> 29079865

[What is new in symptomatic MS treatment: Part 3-bladder dysfunction].

T Henze1, W Feneberg2, P Flachenecker3, D Seidel4, H Albrecht5, M Starck2, S G Meuth6.   

Abstract

The symptomatic treatment of multiple sclerosis (MS) nowadays is of similar importance as immunotherapy within a comprehensive concept of therapy of this chronic disease, since it contributes considerably to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Klinisches Kompetenznetz Multiple Sklerose (KKNMS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation took place. These new findings together with further aspects of disease measures and overall treatment strategies of the respective symptoms, as well as treatment goals are introduced in a series of six individual contributions. Here, the symptoms of bladder dysfunction will be discussed.

Entities:  

Keywords:  Bladder dysfunction; Multiple sclerosis; Review; Symptomatic treatment; Vegetative nervous system

Mesh:

Year:  2018        PMID: 29079865     DOI: 10.1007/s00115-017-0440-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  56 in total

1.  Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial.

Authors:  C Gobbi; G A Digesu; V Khullar; S El Neil; G Caccia; C Zecca
Journal:  Mult Scler       Date:  2011-07-14       Impact factor: 6.312

2.  Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction.

Authors:  L Vahter; I Zopp; M Kreegipuu; P Kool; T Talvik; K Gross-Paju
Journal:  Mult Scler       Date:  2008-11-05       Impact factor: 6.312

Review 3.  Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis.

Authors:  Federica Puccini; Alka Bhide; Suzy Elneil; G Alessandro Digesu
Journal:  Int Urogynecol J       Date:  2015-07-09       Impact factor: 2.894

4.  Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.

Authors:  R B C Kavia; D De Ridder; C S Constantinescu; C G Stott; C J Fowler
Journal:  Mult Scler       Date:  2010-09-09       Impact factor: 6.312

5.  Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study.

Authors:  Simone Di Rezze; Vittorio Frasca; Maurizio Inghilleri; Valentina Durastanti; Antonio Cortese; Elena Giacomelli; Enrico Millefiorini
Journal:  Clin Neuropharmacol       Date:  2012 Sep-Oct       Impact factor: 1.592

Review 6.  Cranberry and urinary tract infections.

Authors:  David R P Guay
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  The effect of pelvic floor muscle training alone or in combination with electrostimulation in the treatment of sexual dysfunction in women with multiple sclerosis.

Authors:  A C Lúcio; C A L D'Ancona; M H B M Lopes; M C Perissinotto; B P Damasceno
Journal:  Mult Scler       Date:  2014-05-29       Impact factor: 6.312

Review 8.  Management of neurogenic bladder in patients with multiple sclerosis.

Authors:  Véronique Phé; Emmanuel Chartier-Kastler; Jalesh N Panicker
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

9.  Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.

Authors:  Claudio Solaro; Roberto Bergamaschi; Cristiana Rezzani; Margit Mueller; Erika Trabucco; Valeria Bargiggia; Francesca Dematteis; Alessandra Mattioda; Vincenzo Cimino; Domenico Restivo; Francesco Patti; Paola Cavalla
Journal:  Clin Neuropharmacol       Date:  2013 Jul-Aug       Impact factor: 1.592

Review 10.  Ensuring patient adherence to clean intermittent self-catheterization.

Authors:  Jai H Seth; Collette Haslam; Jalesh N Panicker
Journal:  Patient Prefer Adherence       Date:  2014-02-12       Impact factor: 2.711

View more
  1 in total

1.  [Current aspects of neurogenic dysfunctions of the lower urinary tract in multiple sclerosis].

Authors:  Burkhard Domurath; Peter Flachenecker; Thomas Henze; Wolfgang Feneberg; Anna Brandt; Ines Kurze; Ruth Kirschner-Hermanns; Albert Kaufmann; Jörn Bremer; Manuela Vonthien; Kerstin Ratering; Christoph Schäfer; Will Nelson Vance; Paul Schmidt
Journal:  Nervenarzt       Date:  2021-01-05       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.